| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to nanoparticles for drug delivery with the nanoparticles consisting of a metal-chelating polymer, and an active agent representing a related TNF ligand inducing apoptosis (TRAIL) wherein the active agent is covalently bond with the polymer. The invention also refers to the pharmaceutical composition for inducing apoptosis in a cancer cell, reducing tumour growth and/or tumour growth inhibition which involves said nanoparticles and a pharmaceutically acceptable carrier. What is also declared is a method for preparing the nanoparticles which involves mixing the aqueous solution of the metal-chelating polymer with a soluble metal salt, oxidation of metal ions and formation of the nanoparticles by reducing pH to a basic level. Then the stages of metal addition, oxidation and reduction to basic pH are performed again. They are followed by nanoparticle functionalisation and contact with TRAIL, and blocking of the rest active sites on the surface of the nanoparticles. n EFFECT: invention provides reducing the effective apoptosis ensured by TRAIL stabilisation, prevented splitting and reduced TRAIL amount required for apoptosis. n 27 cl, 30 dwg, 8 ex |